Narla
Anirudh Narla, New Haven, CT US
Patent application number | Description | Published |
---|---|---|
20150241481 | WIRELESS JOSEPHSON BIFURCATION AMPLIFIER - A wireless Josephson-junction-based amplifier is described that provides improved tunability and increased control over both a quality factor Q and participation ratio p of the amplifier. The device may be fabricated on a chip and mounted in a waveguide. No wire bonding between the amplifier and coaxial cables or a printed circuit board is needed. At least one antenna on the chip may be used to couple energy between the waveguide and wireless JBA. The amplifier is capable of gains greater than 25 dB. | 08-27-2015 |
Aru Narla, Chandler, AZ US
Patent application number | Description | Published |
---|---|---|
20110144853 | MINING METHODOLOGY TO ELIMINATE INAPPROPRIATE SETTING OF ERROR CONDITIONS USING OPERATING PARAMETERS - A system and method for reducing or eliminating built-in tests and diagnostic trouble codes that are set as a result of improper parameter values. The method includes collecting field failure data that identifies diagnostic trouble codes and parameters of the system that are used to set diagnostic trouble codes. The method transforms the collected data into a format more appropriate for human analysis and pre-processes the transferred data to identify and remove information that could bias the human analysis. The method includes plotting linear and nonlinear combinations of operation parameters, performing data mining and analysis for detecting inappropriate settings of fault codes in the pre-processed data and providing the mined data to a subject matter expert for review to determine whether a diagnostic trouble code has been issued because of improper parameters. | 06-16-2011 |
Chandrashekar Narla, Bangalore IN
Patent application number | Description | Published |
---|---|---|
20140177359 | METHOD AND APPARATUS FOR ALIGNING A CLOCK SIGNAL AND A DATA STROBE SIGNAL IN A MEMORY SYSTEM - A method of aligning a clock signal and a data strobe signal in a system comprising a memory controller and a memory, and a corresponding memory system are provided. The method comprising the steps of: putting the memory into a write levelling mode; incrementing an alignment delay applied to the data strobe signal until a transition point occurs at which a response of the memory to issuance of the data strobe signal transitions to an inverse state; performing an oversampling of the response of the memory over a selected interval following said transition point; repeating the steps of incrementing and performing an oversampling until, for a selected alignment delay, a majority of results of the oversampling is in the inverse state; performing a cycle alignment detection procedure to determine an identified clock cycle of a plurality of adjacent cycles of the clock signal, the identified clock cycle responsible for the transition point; and applying the selected alignment delay to the data strobe signal and applying a clock cycle selection to a data path in the system to match the identified clock cycle. | 06-26-2014 |
Goutham Narla, Beachwood, OH US
Patent application number | Description | Published |
---|---|---|
20140213578 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS - Tricyclic chemical modulators of FOXO transcription factor proteins are disclosed. The compounds are useful to treat cancer, age-onset proteotoxicity, stress-induced depression, inflammation, and acne. The compounds are of the following phenothiazine, dibenzoazepine and annulene and similar genera: | 07-31-2014 |
Goutham Narla, New Rochelle, NY US
Patent application number | Description | Published |
---|---|---|
20090325150 | KLF6 ALTERNATIVE SPLICE FORMS AND A GERMLINE KLF6 DNA POLYMORPHISM ASSOCIATED WITH INCREASED CANCER RISK - Disclosed are methods of identifying and diagnosing certain types of cancers and pre-stages thereof in a patient by identifying alternatively spliced isoforms of wild type KLF6 (KLFwt), in particular anyone of the isoforms selected from the group consisting of: KLF6 splice variant-1 (KLF6SV1), KLF6 splice variant-2 (KLF6SV2), and KLF6 splice variant-3 (KLF6SV3). Also disclosed are methods diagnosing cancer using the polypeptides and polynucleotides identified herein, as well as methods of treating certain types of cancers by inhibiting polynucleotides and polypeptides identified herein. | 12-31-2009 |
20110059899 | Kruppel-like factor 6 (KLF6), a tumor suppressor protein, and diagnostics, therapeutics, and screening based on this protein - The present invention relates to identification of tumor suppressor activity of a protein, KLF6 (KLF6), and to related diagnostic and therapeutic compositions and methods. The discovery of this tumor suppressor activity provides screening targets as well, particularly screening for compounds that overcome gene inactivation or alteration. | 03-10-2011 |
20130035243 | KLF6 ALTERNATIVE SPLICE FORMS AND A GERMLINE KLF6 DNA POLYMORPHISM ASSOCIATED WITH INCREASED CANCER RISK - Disclosed are methods of identifying and diagnosing certain types of cancers and pre-stages thereof in a patient by identifying alternatively spliced isoforms of wild type KLF6 (KLF6wt), in particular any one of the isoforms selected from the group consisting of: KLF6 splice variant-1 (KLF6 | 02-07-2013 |
Goutham Narla, New York, NY US
Patent application number | Description | Published |
---|---|---|
20120322792 | Method and Compositions for Treating Cancer and Related Methods - The present invention relates to anti-cancer therapeutics. In certain aspects, cancers are treated with a combination of an anti-EGFR agent and an agent that increases the activity of the KLF6 tumor suppressor gene and/or an agent that increases activity of the FOXO1 tumor suppressor gene. In a preferred aspect, the anti-EGFR agent erlotinib a tricyclic agent compound, are used in combination to treat non-small cell lung cancer in a patient with primary or acquired drug resistance to erlotinib, and wherein the tricyclic agent is administered in an amount that does not lead to a substantial central nervous system effect. In additional aspects, the invention relates to compositions and kits useful for treating cancers, methods for screening for compounds that enhance the activity of anti-EGFR agent, and methods for determining whether a patient will respond to anti-EGFR therapy. | 12-20-2012 |
20150224101 | Method and Compositions for Treating Cancer and Related Methods - The present invention relates to anti-cancer therapeutics. In certain aspects, cancers are treated with a combination of an anti-EGFR agent and an agent that increases the activity of the KLF6 tumor suppressor gene and/or an agent that increases activity of the FOXO1 tumor suppressor gene. In a preferred aspect, the anti-EGFR agent erlotinib a tricyclic agent compound, are used in combination to treat non-small cell lung cancer in a patient with primary or acquired drug resistance to erlotinib, and wherein the tricyclic agent is administered in an amount that does not lead to a substantial central nervous system effect. In additional aspects, the invention relates to compositions and kits useful for treating cancers, methods for screening for compounds that enhance the activity of anti-EGFR agent, and methods for determining whether a patient will respond to anti-EGFR therapy. | 08-13-2015 |
Madan Mohan Narla, North Brunswick, NJ US
Patent application number | Description | Published |
---|---|---|
20120096366 | TECHNIQUE FOR HANDLING URLS FOR DIFFERENT MOBILE DEVICES THAT USE DIFFERENT USER INTERFACE PLATFORMS - The examples provided teach techniques and devices used to route a request received from a mobile station via a URL link that is independent from the user interface platform used on the mobile device. This request is received at a web server which routes the request to an application server based on the URL link. The application identifies the user interface platform used by the mobile station and determines whether the application is supported by that user interface platform. If the application is not supported by the user interface platform, the application server reroutes the request to another application server having the application that is supported by the user interface platform and the application at the other server carries out the request and sends the response to the mobile station. | 04-19-2012 |
Mohandas Narla, New York, NY US
Patent application number | Description | Published |
---|---|---|
20100323393 | Ordered Assembly of Membrane Proteins During Differentiation of Erythroblasts - Disclosed herein are methods for the isolation, identification, and quantification of red blood cells and red blood cell precursors at different developmental stages. Also disclosed are methods for monitoring ex vivo proliferation and differentiation of red blood cells and red blood cell progenitors. | 12-23-2010 |
20120295285 | Ordered Assembly of Membrane Proteins During Differentiation of Erythroblasts - Disclosed herein are methods for the isolation, identification, and quantification of red blood cells and red blood cell precursors at different developmental stages. Also disclosed are methods for monitoring ex vivo proliferation and differentiation of red blood cells and red blood cell progenitors. | 11-22-2012 |
20130209431 | ISOLATION AND CULTURE OF ERYTHROID PROGENITOR CELLS - Disclosed herein are methods of isolating erythroid progenitor cells from a source of human hematopoietic cells and methods of culturing the isolated erythroid progenitor cells in vitro to produce clinically relevant quantities of erythrocytes. | 08-15-2013 |
Nagaraju Narla, Karimnagar IN
Patent application number | Description | Published |
---|---|---|
20150324424 | MANAGEMENT OF PARALLEL USER INPUTS IN ELECTRONIC COMMUNICATIONS - A discussion thread is associated with a master recipients list that is maintained at an author's computer or a server computer. The recipients list is revised as participants in the discussion are added to and/or removed from the discussion. An author is notified when target recipients do not match the master recipients list. When a participant is added to the discussion from an old discussion instance, a thread manager provides for the added participant to receive a more current discussion instance. | 11-12-2015 |
20150326519 | MANAGEMENT OF PARALLEL USER INPUTS IN ELECTRONIC COMMUNICATIONS - A discussion thread is associated with a master recipients list that is maintained at an author's computer or a server computer. The recipients list is revised as participants in the discussion are added to and/or removed from the discussion. An author is notified when target recipients do not match the master recipients list. When a participant is added to the discussion from an old discussion instance, a thread manager provides for the added participant to receive a more current discussion instance. | 11-12-2015 |
Rama Narla, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20130289271 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY - Provided herein are Heteroaryl Compounds having the following structure: | 10-31-2013 |
Rama K. Narla, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20090099178 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF - This invention is directed to Indazole Compounds or pharmaceutically acceptable salts, solvates and hydrates thereof. The Indazole Compounds have utility in the treatment or prevention of a wide range of diseases and disorders that are responsive to the inhibition, modulation or regulation of kinases, such as inflammatory diseases, abnormal angiogenesis and diseases related thereto, cancer, atherosclerosis, a cardiovascular disease, a renal disease, an autoimmune condition, macular degeneration, disease-related wasting, an asbestos-related condition, pulmonary hypertension, diabetes, obesity, pain and others. Thus, methods of treating or preventing such diseases and disorders are also disclosed, as are pharmaceutical compositions comprising one or more of the Indazole Compounds. This invention is based, in part, upon the discovery of a novel class of 5-triazolyl substituted indazole molecules that have potent activity with respect to the modulation of protein kinases. Thus, the invention encompasses orally active molecules as well as parenterally active molecules which can be used at lower doses or serum concentrations for treating diseases or disorders associated with protein kinase signal transduction. | 04-16-2009 |
20100216781 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY - Provided herein are Heteroaryl Compounds having the following structure: | 08-26-2010 |
20120059164 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITOR FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY - Provided herein are Heteroaryl Compounds having the following structure: | 03-08-2012 |
20120071658 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITOR FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY - Provided herein are Heteroaryl Compounds having the following structure: | 03-22-2012 |
20130102613 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS - Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma. | 04-25-2013 |
20130245027 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS - Provided herein are methods for treating or preventing triple negative breast cancer or hormone receptor positive breast cancer, comprising administering an effective amount of a TOR kinase inhibitor to a patient having triple negative breast cancer or hormone receptor positive breast cancer. | 09-19-2013 |
20140113904 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS - Provided herein are methods for treating or preventing prostate cancer, comprising administering an effective amount of a TOR kinase inhibitor to a patient having prostate cancer. | 04-24-2014 |
20140200206 | SUBSTITUTED PYRROLOPYRIMIDINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH - Provided herein are Pyrrolopyrimidine Compounds having the following structure: | 07-17-2014 |
20140200207 | SUBSTITUTED PYRROLOPYRIMIDINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH - Provided herein are Pyrrolopyrimidine Compounds having the following structure: | 07-17-2014 |
20140315900 | METHODS FOR TREATING CANCER USING DIHYDROPYRAZINO-PYRAZINE COMPOUND COMBINATION THERAPY - Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound and an effective amount of an androgen receptor antagonist to a patient having a cancer. | 10-23-2014 |
Sagar Narla, Bellevue, WA US
Patent application number | Description | Published |
---|---|---|
20150294256 | SCENARIO MODELING AND VISUALIZATION - A user provides inputs to model scenarios for which data is to be reported. These scenarios are modeled by aggregating events into activities that are then aggregated, themselves, into scenarios. A scenarios analyzer accesses data logs to extract and analyze data for the modeled scenario. The analyzed data is visualized as a histogram with roll up and drill down functionality. | 10-15-2015 |